JP2023526045A5 - - Google Patents

Info

Publication number
JP2023526045A5
JP2023526045A5 JP2022568765A JP2022568765A JP2023526045A5 JP 2023526045 A5 JP2023526045 A5 JP 2023526045A5 JP 2022568765 A JP2022568765 A JP 2022568765A JP 2022568765 A JP2022568765 A JP 2022568765A JP 2023526045 A5 JP2023526045 A5 JP 2023526045A5
Authority
JP
Japan
Prior art keywords
hcv
nucleic acid
variable domain
composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050437 external-priority patent/WO2021226664A1/en
Publication of JP2023526045A publication Critical patent/JP2023526045A/ja
Publication of JP2023526045A5 publication Critical patent/JP2023526045A5/ja
Pending legal-status Critical Current

Links

JP2022568765A 2020-05-11 2021-05-11 可変ドメイン欠失e2ポリペプチドを含むc型肝炎核酸ワクチン Pending JP2023526045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901506A AU2020901506A0 (en) 2020-05-11 Compositions and their prophylactic or therapeutic use
AU2020901506 2020-05-11
PCT/AU2021/050437 WO2021226664A1 (en) 2020-05-11 2021-05-11 A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide

Publications (2)

Publication Number Publication Date
JP2023526045A JP2023526045A (ja) 2023-06-20
JP2023526045A5 true JP2023526045A5 (cg-RX-API-DMAC7.html) 2024-05-20

Family

ID=78525848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568765A Pending JP2023526045A (ja) 2020-05-11 2021-05-11 可変ドメイン欠失e2ポリペプチドを含むc型肝炎核酸ワクチン

Country Status (8)

Country Link
US (1) US20230181726A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149541A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526045A (cg-RX-API-DMAC7.html)
CN (1) CN115843270A (cg-RX-API-DMAC7.html)
AU (1) AU2021270053A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023101A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178547A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021226664A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12576041B1 (en) * 2021-07-14 2026-03-17 Dean Nakamura Transient expression of biologic materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
CA2610919C (en) * 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
US9079950B2 (en) * 2010-08-04 2015-07-14 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Modified Hepatitis C virus proteins
WO2016141201A2 (en) * 2015-03-04 2016-09-09 University Of Maryland Rational vaccine design for hepatitis c virus
CN110049993A (zh) * 2016-09-29 2019-07-23 麦克法兰布奈特医疗研究与公共健康研究所有限公司 组装的糖蛋白

Similar Documents

Publication Publication Date Title
JP7663622B2 (ja) 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
Christensen et al. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8+ T-cell memory
JP2022160401A5 (cg-RX-API-DMAC7.html)
JP2025084808A (ja) エプスタイン-バーウイルスワクチン
JP2023513720A5 (cg-RX-API-DMAC7.html)
JP2023518340A5 (cg-RX-API-DMAC7.html)
JP2017515508A5 (cg-RX-API-DMAC7.html)
JP2023522154A5 (cg-RX-API-DMAC7.html)
JP2022546402A (ja) ウイルス感染症を処置するための組成物及び方法
Mohapatra Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus
JP2023527083A5 (cg-RX-API-DMAC7.html)
JP2023515806A5 (cg-RX-API-DMAC7.html)
WO2019163781A1 (ja) エンテロウイルスワクチン
AU2016313660A1 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
JP2024523329A5 (cg-RX-API-DMAC7.html)
CA3076263C (en) Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
TWI811248B (zh) 經鼻b型肝炎疫苗組成物及其製造方法
US20160279229A9 (en) Viral Vaccine Vectors
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
JP2022513438A5 (cg-RX-API-DMAC7.html)
JP2025529128A (ja) カスパーゼ活性化及び動員ドメイン(asc)を有するアポトーシス関連スペック様タンパク質を標的化する組成物及び使用方法
CN113227360A (zh) 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒
Gupta Methods and Difficulties in the Creation of the 2019 Coronavirus Disease Vaccine
US20030228327A1 (en) DNA-based plasmid formulations and vaccines and prophylactics containing the same